Welcome to the unCommon Era (0 uCE).

Using the latest technologies to efficiently build drugs that target the underlying cause of rare uncommon diseases

First indication: Rett Syndrome

Neurodevelopmental monogenetic disease that impacts 1 in 10,000 girls

Our uncommon approach

Deep domain and motivated disease experts that truly understand disease from mechanism to patients.

We efficiently validate the best modalities in the disease models we know will translate to patient.

Then drive it to the clinic with focused capital to see impact on first patients.

Our deep disease expertise and uncommon approach has unlocked multiple therapeutics that will improve patient lives and in combination could deliver a cure.